NCT00337610 - Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

190

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

August 31, 2007

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day

Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.

DRUG

comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day

Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY